• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Growth Differentiation Factor-15: A Promising Biomarker and Target in Cancer Patients.

作者信息

Anker Markus S, Bullinger Lars, Keller Ulrich, Khan Muhammad Shahzeb

机构信息

Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine CBF, Berlin, Germany; Charité - University Medicine Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; German Centre for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany; Berlin Institute of Health Center for Regenerative Therapies (BCRT), Berlin, Germany.

Department of Hematology, Oncology, and Cancer Immunology, Charité - University Medicine Berlin, corporate member of Free University Berlin and Humboldt University Berlin, Berlin, Germany; German Cancer Consortium (DKTK), partner site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany; Max Delbrück Center for Molecular Medicine, Berlin, Germany.

出版信息

JACC CardioOncol. 2025 Feb;7(2):153-156. doi: 10.1016/j.jaccao.2025.01.001.

DOI:10.1016/j.jaccao.2025.01.001
PMID:39967201
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11866430/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba17/11866430/c0e75386f2a0/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba17/11866430/5d33db6bcbef/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba17/11866430/c0e75386f2a0/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba17/11866430/5d33db6bcbef/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba17/11866430/c0e75386f2a0/gr1.jpg

相似文献

1
Growth Differentiation Factor-15: A Promising Biomarker and Target in Cancer Patients.生长分化因子-15：癌症患者中有前景的生物标志物和靶点
JACC CardioOncol. 2025 Feb;7(2):153-156. doi: 10.1016/j.jaccao.2025.01.001.
2
Growth Differentiation Factor-15 Predicts Major Bleeding in Cancer Patients: Results From the Vienna CAT-BLED Study.生长分化因子-15预测癌症患者的大出血：维也纳CAT-BLED研究结果
JACC CardioOncol. 2025 Feb;7(2):141-152. doi: 10.1016/j.jaccao.2024.11.007. Epub 2025 Jan 14.
3
Growth differentiation factor-15 predicts major bleeding, major adverse cardiac events and mortality in patients with end-stage kidney disease on haemodialysis: findings from the VIVALDI study.生长分化因子 15 可预测血液透析终末期肾病患者的大出血、主要不良心脏事件和死亡率：来自 VIVALDI 研究的结果。
Nephrol Dial Transplant. 2023 Jul 31;38(8):1836-1847. doi: 10.1093/ndt/gfac321.
4
Growth differentiation factor-15 for prediction of bleeding in cancer patients.生长分化因子-15 预测癌症患者出血风险。
J Thromb Haemost. 2022 Jan;20(1):138-144. doi: 10.1111/jth.15559. Epub 2021 Nov 2.
5
Growth Differentiation Factor-15 Based ABC (Age, Biomarkers, Clinical History)-AF (Atrial Fibrillation)-Bleeding Risk Score for Elderly Patients with Nonvalvular Atrial Fibrillation.基于生长分化因子-15的ABC（年龄、生物标志物、临床病史）-AF（心房颤动）-非瓣膜性心房颤动老年患者出血风险评分
J Healthc Eng. 2022 Mar 8;2022:2863815. doi: 10.1155/2022/2863815. eCollection 2022.
6
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.新型基于生物标志物的 ABC（年龄、生物标志物、临床病史）-房颤患者出血风险评分：一项推导和验证研究。
Lancet. 2016 Jun 4;387(10035):2302-2311. doi: 10.1016/S0140-6736(16)00741-8. Epub 2016 Apr 4.
7
GDF-15: A biomarker-based prediction for bleeding-cardiovascular death.
Eur J Intern Med. 2022 Feb;96:125. doi: 10.1016/j.ejim.2021.12.005. Epub 2021 Dec 12.
8
Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study.生长分化因子-15 水平可预测急性冠脉综合征患者的大出血和心血管事件：来自 PLATO 研究的结果。
Eur Heart J. 2016 Apr 21;37(16):1325-33. doi: 10.1093/eurheartj/ehv491. Epub 2015 Sep 28.
9
Growth Differentiation Factor-15: A Novel Biomarker for Predicting Risk of Venous Thromboembolism and Bleeding in Patients with Cancer.
Thromb Haemost. 2022 Jul;122(7):1075. doi: 10.1055/a-1827-7328. Epub 2022 Apr 18.
10
Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding.急性冠状动脉综合征后1个月时的生长分化因子15与大出血风险增加相关。
J Am Heart Assoc. 2017 Apr 14;6(4):e005580. doi: 10.1161/JAHA.117.005580.

本文引用的文献

1
Growth Differentiation Factor-15 Predicts Major Bleeding in Cancer Patients: Results From the Vienna CAT-BLED Study.生长分化因子-15预测癌症患者的大出血：维也纳CAT-BLED研究结果
JACC CardioOncol. 2025 Feb;7(2):141-152. doi: 10.1016/j.jaccao.2024.11.007. Epub 2025 Jan 14.
2
Ponsegromab for the Treatment of Cancer Cachexia.泊塞格单抗用于治疗癌症恶病质。
N Engl J Med. 2024 Dec 19;391(24):2291-2303. doi: 10.1056/NEJMoa2409515. Epub 2024 Sep 14.
3
2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).
2024年欧洲心脏病学会（ESC）心房颤动管理指南，与欧洲心胸外科学会（EACTS）联合制定。
Eur Heart J. 2024 Sep 29;45(36):3314-3414. doi: 10.1093/eurheartj/ehae176.
4
Role of growth differentiation factor 15 in cancer cachexia (Review).生长分化因子15在癌症恶病质中的作用（综述）
Oncol Lett. 2023 Sep 13;26(5):462. doi: 10.3892/ol.2023.14049. eCollection 2023 Nov.
5
Growth differentiation factor-15 and prediction of cancer-associated thrombosis and mortality: a prospective cohort study.生长分化因子 15 与癌症相关血栓和死亡预测：一项前瞻性队列研究。
J Thromb Haemost. 2023 Sep;21(9):2461-2472. doi: 10.1016/j.jtha.2023.04.043. Epub 2023 May 14.
6
Growth Differentiation Factor 15 and Risk of Bleeding Events: The Atherosclerosis Risk in Communities Study.生长分化因子 15 与出血事件风险：社区动脉粥样硬化风险研究。
J Am Heart Assoc. 2023 Mar 21;12(6):e023847. doi: 10.1161/JAHA.121.023847. Epub 2023 Mar 16.
7
Growth Differentiation Factor-15 Predicts Mortality and Heart Failure Exacerbation But Not Ventricular Arrhythmias in Patients With Cardiomyopathy.生长分化因子-15 可预测心肌病患者的死亡率和心力衰竭恶化，但不能预测室性心律失常。
J Am Heart Assoc. 2023 Feb 7;12(3):e8023. doi: 10.1161/JAHA.122.026003. Epub 2023 Jan 31.
8
2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19.2022 年国际癌症患者静脉血栓栓塞症治疗和预防临床实践指南，包括 COVID-19 患者。
Lancet Oncol. 2022 Jul;23(7):e334-e347. doi: 10.1016/S1470-2045(22)00160-7.
9
Sarcopenia and cachexia in chronic diseases: from mechanisms to treatment.慢性疾病中的肌肉减少症和恶病质：从机制到治疗。
Pol Arch Intern Med. 2021 Dec 22;131(12). doi: 10.20452/pamw.16135. Epub 2021 Nov 15.
10
Growth differentiation factor-15 for prediction of bleeding in cancer patients.生长分化因子-15 预测癌症患者出血风险。
J Thromb Haemost. 2022 Jan;20(1):138-144. doi: 10.1111/jth.15559. Epub 2021 Nov 2.